Treatment of Pemphigus Vulgaris With Pulse Intravenous Cyclophosphamide

Archives of Dermatology

Volumn 128, Issue 12, 1992, Pages 1626-1630

  Pandya, Amit G ^a   Sontheimer, Richard D ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE;

ADULT; ARTICLE; BLISTER; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; MALIGNANT TRANSFORMATION; ORAL DRUG ADMINISTRATION; PEMPHIGUS VULGARIS; PRIORITY JOURNAL; SIDE EFFECT;

ADULT; CASE REPORT; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMAN; INFUSIONS, INTRAVENOUS; MALE; PEMPHIGUS;

EID: 0026690061     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archderm.1992.04530010064010     Document Type: Article

References (48)

1. Gellis S, Glass FA. Pemphigus: a survey of 170 patients admitted to Bellevue hospital from 1911 to 1941. Arch Dermatol Syphilol. 1941; 44: 321-336.
2. Ryan JG. Pemphigus: a 20-year survey of experience with 70 cases. Arch Dermatol. 1971; 104: 14-20.
3. Rosenberg FR, Sanders S, Nelson CT. Pemphigus: a 20-year review of 107 patients treated with corticosteroids. Arch Dermatol. 1976; 112: 962-970.
4. Ahmed AR, Moy R. Death in pemphigus. J Am Acad Dermatol. 1982; 7: 221-228.
5. Lever WF, White H. Treatment of pemphigus with corticosteroids. Arch Dermatol. 1962; 87: 52-66.
6. Lever WF, Schaumburg-Lever G. Treatment of pemphigus vulgaris. Arch Dermatol. 1984; 120: 44-47.
7. Bystryn JC. Adjuvant therapy of pemphigus. Arch Dermatol. 1984; 120: 941-951.
8. Costello MJ, Jaimovitch L, Dannenberg M. Treatment of pemphigus with corticosteroids. JAMA. 1957; 165: 1249-1255.
9. Sanders SL, Brodey M, Nelson CT. Corticosteroid treatment of pemphigus. Arch Dermatol. 1960; 82: 717-724.
10. Lever WF. Methotrexate and prednisone in pemphigus vulgaris: therapeutic results obtained in 36 patients between 1961 and 1970. Arch Dermatol. 1972; 106; 491-497.
11. Krain LS, Landau JW, Newcomer VD. Cyclophosphamide in the treatment of pemphigus vulgaris and bullous pemphigoid. Arch Dermatol. 1972; 106: 657-661.
12. Roenigk HH Jr, Deodhar S. Pemphigus treated with azathioprine. Arch Dermatol. 1973; 107: 353-357.
13. Penneys NS, Eaglstein WH, Indgin S, Phillip F. Gold sodium thiomalate treatment of pemphigus. Arch Dermatol. 1973; 108: 56-60.
14. Lever WF, Schaumburg-Lever G. Immunosuppressants and prednisone in pemphigus vulgaris. Arch Dermatol. 1977; 113: 1236-1241.
15. Aberer W, Wolff-Schreiner EC, Stingl G, Wolff K. Azathioprine in the treatment of pemphigus vulgaris. J Am Acad Dermatol. 1987; 16: 527-533.
16. Ahmed AR, Hombal S. Use of cyclophosphamide in azathioprine failures in pemphigus. J Am Acad Dermatol. 1987; 17: 437-442.
17. Bassett N, Guillot B, Michel B, Meynadier J, Guilhou J. Dapsone as initial treatment in superficial pemphigus. Arch Dermatol. 1987; 123: 783-785.
18. Burton JL, Greaves MW. Azathioprine for pemphigus and pemphigoid: a four-year follow-up. Br J Dermatol. 1974; 91: 103-109.
19. Fellner MJ, Katz JM, McCabe JB. Successful use of cyclophosphamide and prednisone for initial treatment of pemphigus vulgaris. Arch Dermatol. 1978; 114: 889-894.
20. Steinberg AD, Plotz PH, Wolff SM, Wong VG, Agus SG, Decker JL. Cytotoxic drugs in treatment of nonmalignant diseases. Ann Intern Med. 1972; 76: 619-642.
21. Bast RC. Principles of cancer biology: tumor immunology. In: De Vita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. Philadelphia, Pa: JB Lippincott; 1985: 142.
22. Ebringer A, Mackay IR. Pemphigus vulgaris successfully treated with cyclophosphamide. Ann Intern Med. 1969; 71: 125-127.
23. Carette S, Klippel JH, Decker JL, et al. Controlled studies of oral immunosuppressive drugs in lupus nephritis: a long-term follow-up. Ann Intern Med. 1983; 99: 1-8.
24. McDonald CJ. Cytotoxic agents for use in dermatology I. J Am Acad Dermatol. 1985; 12: 753-775.
25. Gilchrist DM, Friedman JM. Teratogenesis and IV cyclophosphamide. J Rheumatol. 1989; 16: 1008.
26. Ahmed AR, Hombal SM. Cyclophosphamide. J Am Acad Dermatol. 1984; 11: 1115-1126.
27. Hoover R, Fraumeni JF. Risk of cancer in renal transplant recipients. Lancet. 1973; 2: 55-57.
28. Dinant HJ, Decker JL, Klippel JH, Balow JE, Plotz PH Steinberg AD. Alternative modes of cyclophosphamide and azath[ill] oprine therapy in lupus nephritis. Ann Intern Med. 1982; 96: 728-73[ill]
29. Austin HA, Klippel JH, Balow JE, et al. Therapy of lupus ne[ill] phritis: controlled trial of prednisone and cytotoxic drugs. N Engl J Med. 1986; 314: 614-619.
30. Boumpas DT, Yamada H, Patronas NJ, Scott D, Klippel JH Balow JE. Pulse cyclophosphamide for severe neuropsychiatr[ill] lupus. Q J Med. 1991; 81: 975-984.
31. Shibasaki T, Matsumoto H, Ohno I, et al. Effect of cyclopho[ill] phamide pulse therapy in a patient with intractable lupus [ill] Jpn J Med. 1990; 29: 414-416.
32. Moriuchi J, Ichikawa Y, Takaya M, Shimizu H, Kurata T, An[ill]mori S. A case of lupus nephritis resistant to steroid pulse therap[ill] markedly improved by bolus intravenous cyclophosphamide therapy. Ryumachi. 1989; 29: 291-296.
33. McCune WJ, Golbus J, Zeldes W, Bohlke P, Dunne R, Fox DA [ILL] Clinical and immunologic effects of monthly administration of intra[ill] venous cyclophosphamide in severe systemic lupus erythematosu[ill] N Engl J Med. 1988; 318: 1423-1431.
34. Haubitz M, Frei U, Rother U, Brunkhorst R, Koch KM. Cy[ill] clophosphamide pulse therapy in Wegener's granulomatosis. Nepl[ill] rol Dial Transplant. 1991; 6: 531-535.
35. Hoffman GS, Leavitt RY, Fleisher TA, Minor JR, Fauci AS [ill] Treatment of Wegener's granulomatosis with intermittent high-dos[ill] intravenous cyclophosphamide. Am J Med. 1990; 89: 403-410.
36. Du LT, Fain O, Wechsler B, et al. Value of 'bolus' cyclophos[ill] phamide injections in Behcet's disease: experience of 17 cases. Press[ill] Med Paris. 1990; 19: 1355-1358.
37. Tietjen DP, Moore WJ. Treatment of rapidly progressive[ill] glomerulonephritis due to Behcet's syndrome with intravenous cy[ill] clophosphamide. Nephron. 1990; 55: 69-73.
38. Kono DH, Klashman DJ, Gilbert RC. Successful IV pulse cy[ill] clophosphamide in refractory polymyositis in 3 patients with SLE[ill] J Rheumatol. 1990; 17: 982-983.
39. Fort JG, Abruzzo JL. Reversal of progressive necrotizin[ill] vasculitis with intravenous pulse cyclophosphamide and methylpred[ill] nisolone. Arthritis Rheum. 1988; 31: 1194-1198.
40. Gibbons RB, Westerman E. Acute nonlymphocytic leukemi[ill] following short-term, intermittent, intravenous cyclophosphamid[ill] treatment of lupus nephritis. Arthritis Rheum. 1988; 31: 1552-1554[ill]
41. Bergsagel DE, Rider WD. Plasma cell neoplasms. In: Devit[ill] VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practi[ill] of Oncology. Philadelphia, Pa: JB Lippincott; 1985: 1764-1766.
42. Tan-Lim R, Bystryn JC. Effect of plasmapheresis therapy o[ill] circulating levels of pemphigus antibodies. J Am Acad Dermato[ill] 1990; 22: 35-40.
43. Euler HH, LÖffler H, Christophers E. Synchronization[ill] plasmapheresis and pulse cyclophosphamide therapy in pemphigu[ill] vulgaris. Arch Dermatol. 1987; 123: 1205-1210.
44. Schroeder JO, Euler HH, LÖffler H. Synchronization of plas[ill] mapheresis and pulse cyclophosphamide in severe systemic lupu[ill] erythematosus. Ann Intern Med. 1987; 107: 344-346.
45. Dau PC, Callahan J, Parker R, Golbus J. Immunologic effect[ill] of plasmapheresis synchronized with pulse cyclophosphamide i[ill] systemic lupus erythematosus. J Rheumatol. 1991; 18: 270-276.
46. Pasricha JS, Thanzama J, Khan UK. Intermittent high-dos[ill] dexamethasone-cyclophosphamide therapy for pemphigus. Br[ill] Dermatol. 1988; 119: 73-77.
47. Judd KP, Lever WF. Correlation of antibodies in skin and s[ill] rum with disease severity in pemphigus. Arch Dermatol. 1979; 115[ill] 428-432.
48. Stillwell TJ, Benson RC Jr. Cyclophosphamide-induced hen[ill] orrhagic cystitis: a review of 100 patients. Cancer. 1988; 61: 451-455[ill]